Price movement over the last 24 hours
AdaptHealth Corp vs Applovin Corporation — how do they compare? AdaptHealth Corp trades at $10.06 (market cap $1.38B), while Applovin Corporation trades at $523.72 (market cap $177.37B). The key difference: Applovin Corporation is far larger — about 128.5× AdaptHealth Corp's market cap, and Applovin Corporation is trading nearer its 52-week high, AdaptHealth Corp nearer its low. Which is the better fit depends on your goals.
| AHCO | APP | |
|---|---|---|
Market Cap | $1.38B | $177.37B |
Sector | Health | Technology |
52-Week High | $13.38 | $733.60 |
52-Week Low | $8.68 | $335.10 |
Enterprise Value | $3.33B | $178.12B |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $10.27, down 4.55% today, with neutral technical signals and mixed fundamental performance. The company reported Q1 2026 earnings miss with negative EPS of -$0.06 versus $0.0125 expected, continuing a pattern of recent quarterly misses. Despite revenue growth to $3.3B projected for 2026, net income remains negative with -2.43% margin. Analyst consensus remains bullish with 75% buy ratings and $14.80 price target, representing 44% upside potential from current levels.
The investment case balances strong analyst support and reasonable valuation (P/S 0.42, EV/EBITDA 7.17) against persistent profitability challenges. Recent refinancing improves financial flexibility, but execution on cost controls and margin improvement remains critical. The stock offers significant upside if management can translate revenue growth into sustainable profitability, though current negative earnings trend presents near-term headwinds.
AppLovin (APP) trades at $543.79, up 3.17% with strong technical momentum and bullish analyst sentiment. The stock demonstrates exceptional profitability with 64.29% net income margins and consistent earnings beats. Recent Q1 2026 results showed $3.56 EPS beating expectations, while technical indicators signal bullish momentum with key resistance at $554. The company's AI-powered advertising platform drives robust revenue growth, with 2026 revenue projected at $6.2 billion.
AppLovin presents compelling growth potential with 88% analyst buy ratings and $644.09 consensus price target, offering 18% upside. However, premium valuations (P/E 47.29, P/S 30.03) and competitive pressures in mobile advertising represent key risks. The upcoming Q2 2026 earnings on August 5th will be crucial for validating the AI growth narrative and sustaining current momentum.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →